Literature DB >> 25160736

Does the extent of resection impact survival for duodenal adenocarcinoma? Analysis of 1,611 cases.

Jordan M Cloyd1, Jeffrey A Norton, Brendan C Visser, George A Poultsides.   

Abstract

BACKGROUND: Because duodenal adenocarcinoma (DA) is relatively rare, few studies have investigated the impact of resection type on long-term outcomes.
METHODS: The Surveillance, Epidemiology, and End Results database was used to identify all patients between 1988 and 2010 with DA. Patients were divided into two groups based on the type of surgery received: simple resection (SR), defined as a simple removal of the primary site, and radical resection (RR), defined as removal of the primary site with a resection in continuity with other organs. Differences in disease-specific survival (DSS) and overall survival (OS) were compared.
RESULTS: Of the 1,611 patients included, 746 (46.3 %) underwent SR and 865 (53.7 %) underwent RR. As expected, patients undergoing RR were more likely to present with poorly differentiated and large tumors, as well as advanced stage disease. Despite greater lymph node (LN) retrieval (11.0 vs. 6.8; p < 0.0001), RR was not associated with improved survival (5-year DSS and OS rates of 52.8 and 41.3 % for SR vs. 48.8 and 37.6 % for RR; p > 0.05). On univariate Cox proportional hazards regression analysis, the type of surgery was not associated with OS (odds ratio [OR] 0.98; 95 % confidence interval [CI] 0.87-1.11). Increasing TNM stages, tumor grade, fewer LNs removed, LN ratio, and absence of radiation were associated with worse survival. After controlling for confounding factors, type of surgery still did not influence OS (OR 1.11; 95 % CI 0.97-1.27).
CONCLUSIONS: Radical resection (e.g., in the form of pancreaticoduodenectomy) does not appear to impact survival compared with simple segmental resection for DA.

Entities:  

Mesh:

Year:  2014        PMID: 25160736     DOI: 10.1245/s10434-014-4020-z

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  19 in total

1.  Prognostic Impact of Pancreatic Invasion in Duodenal Carcinoma: A Single-Center Experience.

Authors:  Nobuhito Nitta; Katsuhisa Ohgi; Teiichi Sugiura; Yukiyasu Okamura; Takaaki Ito; Yusuke Yamamoto; Ryo Ashida; Keiko Sasaki; Katsuhiko Uesaka
Journal:  Ann Surg Oncol       Date:  2020-05-04       Impact factor: 5.344

2.  Side-to-side duodenojejunostomy after resection of third and fourth duodenal portions with pancreatic preservation.

Authors:  Gerardo Blanco-Fernández; Adela Rojas-Holguín; Noelia De-Armas-Conde; Isabel Gallarín-Salamanca; Diego López-Guerra; Isabel Jaén-Torrejimeno
Journal:  Updates Surg       Date:  2020-06-05

Review 3.  Limited resection vs. pancreaticoduodenectomy for primary duodenal adenocarcinoma: a systematic review and meta-analysis.

Authors:  Pipit Burasakarn; Ryota Higuchi; Souya Nunobe; Shingo Kanaji; Hidetoshi Eguchi; Ken-Ichi Okada; Tsutomu Fujii; Yuichi Nagakawa; Kengo Kanetaka; Hiroharu Yamashita; Suguru Yamada; Shinji Kuroda; Toru Aoyama; Takahiro Akahori; Kenji Nakagawa; Masakazu Yamamoto; Hiroki Yamaue; Masayuki Sho; Yasuhiro Kodera
Journal:  Int J Clin Oncol       Date:  2021-01-01       Impact factor: 3.402

4.  Segmental resection with partial mesopancreatic and mesojejunal excision (pMME) for duodenal carcinoma of the third or fourth portion.

Authors:  Ryota Ito; Yoshihiro Mise; Yu Takahashi; Yosuke Inoue; Fumihiro Kawano; Haruka Tanaka; Shoichi Irie; Hirofumi Ichida; Ryuji Yoshioka; Akio Saiura
Journal:  Langenbecks Arch Surg       Date:  2022-05-30       Impact factor: 2.895

Review 5.  Clinical practice guidelines for duodenal cancer 2021.

Authors:  Kenji Nakagawa; Masayuki Sho; Mitsuhiro Fujishiro; Naomi Kakushima; Takahiro Horimatsu; Ken-Ichi Okada; Mikitaka Iguchi; Toshio Uraoka; Motohiko Kato; Yorimasa Yamamoto; Toru Aoyama; Takahiro Akahori; Hidetoshi Eguchi; Shingo Kanaji; Kengo Kanetaka; Shinji Kuroda; Yuichi Nagakawa; Souya Nunobe; Ryota Higuchi; Tsutomu Fujii; Hiroharu Yamashita; Suguru Yamada; Yukiya Narita; Yoshitaka Honma; Kei Muro; Tetsuo Ushiku; Yasuo Ejima; Hiroki Yamaue; Yasuhiro Kodera
Journal:  J Gastroenterol       Date:  2022-10-19       Impact factor: 6.772

6.  Widespread lymph node recurrence of major duodenal papilla cancer following pancreaticoduodenectomy.

Authors:  Bai-Sen Li; Hui Shi; Min Wen; Ming-Yong Xiao; Jian Wang
Journal:  World J Gastroenterol       Date:  2015-12-28       Impact factor: 5.742

Review 7.  Duodenal adenocarcinoma: Advances in diagnosis and surgical management.

Authors:  Jordan M Cloyd; Elizabeth George; Brendan C Visser
Journal:  World J Gastrointest Surg       Date:  2016-03-27

Review 8.  Small Bowel Adenocarcinoma.

Authors:  Emerson Y Chen; Gina M Vaccaro
Journal:  Clin Colon Rectal Surg       Date:  2018-09-04

9.  Methylation of MGMT Is Associated with Poor Prognosis in Patients with Stage III Duodenal Adenocarcinoma.

Authors:  Tao Fu; Anup Sharmab; Fei Xie; Yanliang Liu; Kai Li; Weiwei Wan; Stephen B Baylin; Christopher L Wolfgang; Nita Ahuja
Journal:  PLoS One       Date:  2016-09-19       Impact factor: 3.240

10.  Prognostic Factors and Clinical Characteristics of Patients with Primary Duodenal Adenocarcinoma: A Single-Center Experience from China.

Authors:  Qing-Long Jiang; Xiang-Hui Huang; Ying-Tai Chen; Jian-Wei Zhang; Cheng-Feng Wang
Journal:  Biomed Res Int       Date:  2016-12-27       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.